Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: Results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)

Circulation

Volumn 137, Issue 14, 2018, Pages 1450-1459

  Udell, Jacob A ^a   Yuan, Zhong ^b   Rush, Toni ^c   Sicignano, Nicholas M ^d   Galitz, Michael ^d   Rosenthal, Norman ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c Health ResearchTx   (United States)

^d NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

Author keywords

diabetes mellitus; diabetic therapy; heart failure; outcomes research; safety

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; BROMOCRIPTINE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; MIGLITOL; NATEGLINIDE; REPAGLINIDE; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

AGED; ALL CAUSE MORTALITY; ARMY; ARTICLE; BELOW KNEE AMPUTATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH CARE SYSTEM; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; UNITED STATES; AMPUTATION; CAUSE OF DEATH; MIDDLE AGED; MORTALITY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AMPUTATION; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85048347907     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.031227     Document Type: Article

References (28)

1. Perkins BA, Udell JA, Cherney DZ. No need to sugarcoat the message: is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis? Am J Kidney Dis. 2016;68:349-352. doi: 10.1053/j.ajkd.2016.03.410.
2. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752-772. doi: 10.1161/CIRCULATIONAHA. 116.021887.
3. Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, Neal B. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411-419. doi: 10.1016/S2213-8587(16)00052-8.
4. Secrest MH, Udell JA, Filion KB. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. Trends Cardiovasc Med. 2017;27:194-202. doi: 10.1016/j.tcm.2017.01.009.
5. Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail. 2017;19:43-53. doi: 10.1002/ejhf.633.
6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720.
7. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Trial Investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526-1534. doi: 10.1093/eurheartj/ehv728.
8. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. doi: 10.1056/NEJMoa1611925.
9. Cherney DZ, Udell JA. Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists: with great power comes great responsibility. Circulation. 2016;134:1915-1917. doi: 10.1161/CIRCULATIONAHA. 116.024764.
10. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015;3:356-366. doi: 10.1016/S2213-8587(15)00044-3.
11. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136:249-259. doi: 10.1161/CIRCULATIONAHA. 117.029190.
12. Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376:2300-2302. doi: 10.1056/NEJMc1701990.
13. Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017;5:680-681. doi: 10.1016/S2213-8587(17)30257-7.
14. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC) EMA/PRAC/637349/2016. February 9, 2017. http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/ human/002672/WC500230719.pdf. Accessed November 10, 2017.
15. U.S. Food and Drug Administration. FDA drug safety communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. September 10, 2015. https://www.fda.gov/Drugs/ DrugSafety/ucm461449.htm. Accessed November 10, 2017.
16. U.S. Food and Drug Administration. FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). June 14, 2016. https://www.fda.gov/Drugs/DrugSafety/ucm505860.htm. Accessed November 10, 2017.
17. U.S. Food and Drug Administration. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). May 16, 2017. https://www.fda.gov/Drugs/ DrugSafety/ucm557507.htm. Accessed November 10, 2017.
18. National Diabetes Statistics Report. 2017. https://www.cdc.gov/diabetes/ pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed September 7, 2017.
19. Udell JA, Wang TY, Li S, Kohli P, Roe MT, de Lemos JA, Wiviott SD. Clinical trial participation after myocardial infarction in a national cardiovascular data registry. JAMA. 2014;312:841-843. doi: 10.1001/jama.2014.6217.
20. Dorrance KA, Ramchandani S, Neil N, Fisher H. Leveraging the military health system as a laboratory for health care reform. Mil Med. 2013;178:142-145.
21. Health ResearchTx. U.S. Department of Defense Military Health System EASEL Dataset 4/01/2013-12/31/2016. http://www.healthresearchtx.com. Accessed November 10, 2017.
22. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
23. Stuart EA, Ialongo NS. Matching methods for selection of subjects for follow-up. Multivariate Behav Res. 2010;45:746-765. doi: 10.1080/00273171.2010.503544.
24. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Series B Stat Methodol. 1996;58:267-228.
25. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150-161. doi: 10.1002/pst.433.
26. Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P; CNODES Investigators. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374:1145-1154. doi: 10.1056/NEJMoa1506115.
27. Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther. 2017;34:1707-1726. doi: 10.1007/s12325-017-0573-0.
28. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-841.